Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 75   

Articles published

ARNA 4.02 -0.03 (-0.74%)
price chart
Why Arena Pharmaceuticals, Inc. Stock Crashed By 31% in 2014
Since the year began, the SPDR S&P Biotech ETF has soared 22%. By comparison, shareholders in Arena Pharmaceuticals (NASDAQ: ARNA ) have endured a multi-month downtrend, with their stock down 31% year-to-date and underperforming the biotech ...
Related articles »  
Surprising New Competitor: Should Arena Pharmaceuticals, Inc. and Orexigen ...
Arena Pharmaceuticals (NASDAQ: ARNA ) and Orexigen's (NASDAQ: OREX ) novel anti-obesity pills are among three drugs that the FDA has approved for use alongside diet and exercise to promote weight loss.
Novo, Orexigen Join Race For Obesity Drugs; Arena-Eisai's Belviq And ...  Bidness ETC
Arena And Vivus Ruined The FDA Approval Run Up For Orexigen  Seeking Alpha (registration)
Related articles »  
Arena Pharmaceuticals - A Biotech Value Investment
It has been some time since I have written an article covering Arena Pharmaceuticals (NASDAQ:ARNA), and I have recently received inquiries asking if I still believe in the company and the prospects for its lead drug, Belviq. Given the stock is hitting ...
Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax ...
Investor-Edge has initiated coverage on the following equities: Exelixis Inc. EXEL, -2.09% Arena Pharmaceuticals Inc. ARNA, -0.74% Novavax Inc. NVAX, -1.24% Dendreon Corporation DNDN, +0.00% and Amicus Therapeutics Inc. FOLD, -4.55% Free ...
Related articles »  
Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary ...
SAN DIEGO, Sept. 2, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. ARNA, -0.74% today announced that the US Food and Drug Administration (FDA) has granted orphan drug status to APD811 for the treatment of pulmonary arterial hypertension.
Arena Pharmaceuticals' APD811 Gets Orphan Drug Status - Analyst Blog  NASDAQ
Related articles »  
Rebounding Stocks: Arena Pharmaceuticals, Inc.(NASDAQ:ARNA), KiOr Inc ...
Arena Pharmaceuticals, Inc.(NASDAQ:ARNA) traded for as little as $3.82 today, a new 52 week low for the company. However, the company's closing price reflected an eight cent boost from the figure recorded on Sept.
Morning Buzz: CenturyLink (NYSE:CTL), Arena Pharmaceuticals (NASDAQ ...
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) and Eisai Inc. announced that data from the Phase 3 clinical trial program for BELVIQ (lorcaserin HCl) CIV will be presented at the American Society of Bariatric Physicians' (ASBP) 64th Annual Obesity ...
Hot Watch List: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Galena ...
On 4 September Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) said that stock analysts at Credit Suisse assumed coverage on shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) in a report issued on Thursday. The firm set an �underperform� rating on ...
Related articles »  
Belviq Sales Trends - A Realistic Look (ARNA)
What I have done in this exercise is to plot linear trend lines to the anti-obesity pill Belviq from Arena Pharmaceuticals (NASDAQ:ARNA). The charts below look at trend lines at 6 months, 12 months, cumulative, and using just 2014 data. What should be ...
Related articles »  
Stocks on Trader's Radar - Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Plug ...
Houston, TX - 12 SEP, 2014 - (Techsonian) - Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) is pleased to report that the US Food and Drug Administration (FDA) has granted orphan drug status to APD811 for the treatment of pulmonary arterial hypertension.